124 related articles for article (PubMed ID: 7780033)
1. Soluble interleukin 6 receptor is biologically active in vivo.
Mackiewicz A; Wiznerowicz M; Roeb E; Karczewska A; Nowak J; Heinrich PC; Rose-John S
Cytokine; 1995 Feb; 7(2):142-9. PubMed ID: 7780033
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6-type cytokines and their receptors for gene therapy of melanoma.
Mackiewicz A; Wiznerowicz M; Roeb E; Nowak J; Pawlowski T; Baumann H; Heinrich PC; Rose-John S
Ann N Y Acad Sci; 1995 Jul; 762():361-73; discussion 373-4. PubMed ID: 7668537
[TBL] [Abstract][Full Text] [Related]
3. Effect of interleukin-6 on the growth of human lung cancer cell line.
Fu J; Zheng J; Fang W; Wu B
Chin Med J (Engl); 1998 Mar; 111(3):265-8. PubMed ID: 10374431
[TBL] [Abstract][Full Text] [Related]
4. The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells.
Ozbek S; Peters M; Breuhahn K; Mann A; Blessing M; Fischer M; Schirmacher P; Mackiewicz A; Rose-John S
Oncogene; 2001 Feb; 20(8):972-9. PubMed ID: 11314032
[TBL] [Abstract][Full Text] [Related]
5. Soluble IL-6 receptor leads to a paracrine modulation of the IL-6-induced hepatic acute phase response in double transgenic mice.
Peters M; Odenthal M; Schirmacher P; Blessing M; Fattori E; Ciliberto G; Meyer zum Buschenfelde KH; Rose-John S
J Immunol; 1997 Aug; 159(3):1474-81. PubMed ID: 9233646
[TBL] [Abstract][Full Text] [Related]
6. In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6.
Peters M; Blinn G; Solem F; Fischer M; Meyer zum Büschenfelde KH; Rose-John S
J Immunol; 1998 Oct; 161(7):3575-81. PubMed ID: 9759879
[TBL] [Abstract][Full Text] [Related]
7. Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components.
Ganapathi MK; Weizer AK; Borsellino S; Bukowski RM; Ganapathi R; Rice T; Casey G; Kawamura K
Cell Growth Differ; 1996 Jul; 7(7):923-9. PubMed ID: 8809410
[TBL] [Abstract][Full Text] [Related]
8. Role of IL-6 and the soluble IL-6 receptor in inhibition of VCAM-1 gene expression.
Oh JW; Van Wagoner NJ; Rose-John S; Benveniste EN
J Immunol; 1998 Nov; 161(9):4992-9. PubMed ID: 9794436
[TBL] [Abstract][Full Text] [Related]
9. Unmasking by soluble IL-6 receptor of IL-6 effect on metastatic melanoma: growth inhibition and differentiation of B16-F10.9 tumor cells.
Oh JW; Katz A; Harroch S; Eisenbach L; Revel M; Chebath J
Oncogene; 1997 Jul; 15(5):569-77. PubMed ID: 9247310
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 receptor-interleukin-6 fusion proteins with enhanced interleukin-6 type pleiotropic activities.
Chebath J; Fischer D; Kumar A; Oh JW; Kolett O; Lapidot T; Fischer M; Rose-John S; Nagler A; Slavin S; Revel M
Eur Cytokine Netw; 1997 Dec; 8(4):359-65. PubMed ID: 9459615
[TBL] [Abstract][Full Text] [Related]
11. Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma.
Campo S; Serlupi-Crescenzi O; Arseni B; Rossi S; Saggio I; Salone B; Cherubini G; Carminati P; De Santis R
Cytokine; 2005 Sep; 31(5):368-74. PubMed ID: 16061391
[TBL] [Abstract][Full Text] [Related]
12. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses.
Müller-Newen G; Küster A; Hemmann U; Keul R; Horsten U; Martens A; Graeve L; Wijdenes J; Heinrich PC
J Immunol; 1998 Dec; 161(11):6347-55. PubMed ID: 9834125
[TBL] [Abstract][Full Text] [Related]
13. Signal through gp130 activated by soluble interleukin (IL)-6 receptor (R) and IL-6 or IL-6R/IL-6 fusion protein enhances ex vivo expansion of human peripheral blood-derived hematopoietic progenitors.
Kimura T; Wang J; Minamiguchi H; Fujiki H; Harada S; Okuda K; Kaneko H; Yokota S; Yasukawa K; Abe T; Sonoda Y
Stem Cells; 2000; 18(6):444-52. PubMed ID: 11072033
[TBL] [Abstract][Full Text] [Related]
14. Endothelial cell protein S synthesis is upregulated by the complex of IL-6 and soluble IL-6 receptor.
Hooper WC; Phillips DJ; Evatt BL
Thromb Haemost; 1997 May; 77(5):1014-9. PubMed ID: 9184420
[TBL] [Abstract][Full Text] [Related]
15. Linked in vivo expression of soluble interleukin-4 receptor and interleukin-4 in murine schistosomiasis.
Fernandez-Botran R; Wynn TA; Hieny S; Caspar P; Chilton PM; Sher A
Eur J Immunol; 1995 Mar; 25(3):649-56. PubMed ID: 7705393
[TBL] [Abstract][Full Text] [Related]
16. Effect of soluble interleukin-6 receptor on interleukin-6 synthesis in human skin fibroblasts.
Cichy J; Rose-John S; Pryjma J; Travis J
Biochem Biophys Res Commun; 1996 Oct; 227(2):318-21. PubMed ID: 8878515
[TBL] [Abstract][Full Text] [Related]
17. Two distinct stimulus-dependent pathways lead to production of soluble murine interleukin-4 receptor.
Blum H; Wolf M; Enssle K; Röllinghoff M; Gessner A
J Immunol; 1996 Sep; 157(5):1846-53. PubMed ID: 8757301
[TBL] [Abstract][Full Text] [Related]
18. Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo.
Parker SE; Khatibi S; Margalith M; Anderson D; Yankauckas M; Gromkowski SH; Latimer T; Lew D; Marquet M; Manthorpe M; Hobart P; Hersh E; Stopeck AT; Norman J
Cancer Gene Ther; 1996; 3(3):175-85. PubMed ID: 8725882
[TBL] [Abstract][Full Text] [Related]
19. [Effect of IL-6/sIL-6R on ex vivo expansion of human cord blood derived CD34+ cells].
Feng JF; Zhuang M; Zhu LJ; Sheng ZL; Zhu YQ; Li CP
Ai Zheng; 2004 Jun; 23(6):715-8. PubMed ID: 15191679
[TBL] [Abstract][Full Text] [Related]
20. Role of interleukin (IL)-2 and IL-15 in the tumour progression of a melanoma cell line MELP, derived from an IL-2 progressor patient.
Doucet C; Meazza R; Pottin-Clemenceau C; Scudeletti M; Brouty-Boye D; Ferrini S; Alileche A; Taoufik Y; Jasmin C; Azzarone B; Indiveri F
Melanoma Res; 1997 Aug; 7 Suppl 2():S7-17. PubMed ID: 9578412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
